Skip to main content
. 2022 Aug 4;12:985470. doi: 10.3389/fonc.2022.985470

Figure 4.

Figure 4

Circ_0007534 suppresses the sensitivity of endometrial cancer cells to paclitaxel. (A, B) The indicated HEC-1 (A) and Ishikawa (B) cells were treated with various concentrations of Paclitaxel for 24 hours, and cell viability was determined using a CCK-8 assay. (C, D) The activities of caspase-3 and caspase-7 in HEC-1 (C) and Ishikawa (D) cells were analyzed with Caspase-Glo 3/7 assays. ***P < 0.001.